Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Apricus Biosciences, Inc. (NASDAQ: APRI).

Full DD Report for APRI

You must become a subscriber to view this report.


Recent News from (NASDAQ: APRI)

Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for t...
Source: Thomson Reuters ONE
Date: May, 03 2018 16:01
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2018 and provided a corporate update on its near-te...
Source: GlobeNewswire
Date: May, 03 2018 16:01
Apricus Bio has work to do before refiling U.S. marketing application for ED cream Vitaros; shares down 10% premarket
Nano cap Apricus Biosciences (NASDAQ: APRI ) slips  10%  premarket on light volume on the heels of FDA feedback that it needs to develop a new less-concentrated formulation of erectile dysfunction (ED) cream Vitaros (alprostadil, DDAIP.HCL) and conduct two new Phase 3 studies wit...
Source: SeekingAlpha
Date: April, 16 2018 08:11
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative med...
Source: GlobeNewswire
Date: April, 16 2018 07:00
Apricus Biosciences Announces Closing of $3.55 Million Public Offering
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public offering of an aggregate of approximately 7.1 million...
Source: GlobeNewswire
Date: April, 04 2018 16:01
Understanding Binary Catalysts: A Brief Guide For Biotech Investors
This article was co-authored by Stepan Lavrouk. Stepan is an investment analyst with Almington Capital. We have written extensively on Seeking Alpha about a range of biotech stocks. But we have also spent some time addressing the activity of biotech investing itself. In previous articles...
Source: SeekingAlpha
Date: March, 29 2018 02:38
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a public offering of an aggregate of approximately 7.1 million shares of common s...
Source: GlobeNewswire
Date: March, 28 2018 08:00
Apricus Biosciences -27% on offering of stock, warrants
Apricus Biosciences (NASDAQ: APRI ) is off 26.7% after hours following word of a public offering of common stock and warrants . More news on: Apricus Biosciences, Inc, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 27 2018 18:51
Apricus Biosciences Announces Proposed Public Offering
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common stock and warrants to purchase shares of...
Source: GlobeNewswire
Date: March, 27 2018 16:32
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. Food and Drug Administration (“FDA”) to d...
Source: GlobeNewswire
Date: March, 26 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.2680.2856390.3090.268452,559
2018-08-160.2660.2750.2750.26683,031
2018-08-150.27040.26620.2740.266296,754
2018-08-140.2710.27210.27990.27111,172
2018-08-130.28030.27990.28030.2721153,183

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17130,721219,18859.6388Short
2018-08-1623,52830,10078.1661Short
2018-08-1529,02565,32844.4296Short
2018-08-1414,36325,41356.5183Short
2018-08-1329,97144,12967.9168Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APRI.


About Apricus Biosciences, Inc. (NASDAQ: APRI)

Logo for Apricus Biosciences, Inc. (NASDAQ: APRI)

Not available

 

Contact Information

 

 

Current Management

  • Y. Joseph Mo / President, CEO
  • Joseph M. Warusz / CFO

Current Share Structure

  • Market Cap: $6,821,354 - 05/14/2018
  • Issue and Outstanding: 23,441,080 - 04/27/2018

 


Recent Filings from (NASDAQ: APRI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 06 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (NASDAQ: APRI)

Daily Technical Chart for (NASDAQ: APRI)


Stay tuned for daily updates and more on (NASDAQ: APRI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: APRI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APRI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of APRI and does not buy, sell, or trade any shares of APRI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/